Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas van Baren

Showing results (1-10 of 48) with videos related to

Pageof 5
Sort By:
The New England Journal of Medicine|January 17, 2003
Immunosurveillance against cancer and immunotherapy--synergy or antagonism?Thierry Boon, Nicolas van Baren
Annals of the New York Academy of Sciences|May 9, 2013
Ongoing adaptive immune responses in the microenvironment of melanoma metastasesNicolas van Baren, Pierre G Coulie
Cancer Immunology Research|August 14, 2015
Tumoral Immune Resistance Mediated by Enzymes That Degrade TryptophanNicolas van Baren, Benoît J Van den Eynde
Seminars in Oncology|October 31, 2002
Peptide-based cancer vaccinesJean-Pascal Machiels, Nicolas van Baren, Marie Marchand
Frontiers in Immunology|February 19, 2015
Tryptophan-degrading enzymes in tumoral immune resistanceNicolas van Baren, Benoît J Van den Eynde
Journal of the European Academy of Dermatology and Venereology : JEADV|January 25, 2007
Is serum galectin-3 a potential predictor of the response to active specific immunotherapy in melanoma patients?Pierre Vereecken, Michel Heenen, Sajida Babar, et al.
Oncoimmunology|March 14, 2013
Lymphoid neogenesis in melanoma: What does it tell us?Nicolas van Baren, Jean-François Baurain, Pierre G Coulie
Cancer Immunology, Immunotherapy : CII|May 10, 2011
Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?Arcadi Cipponi, Grégoire Wieers, Nicolas van Baren, et al.
Oncoimmunology|July 9, 2015
Expression profile of the human IDO1 protein, a cancer drug target involved in tumoral immune resistanceNathalie Vigneron, Nicolas van Baren, Benoît J Van den Eynde
Molecular Cancer|December 19, 2007
Human periostin gene expression in normal tissues, tumors and melanoma: evidences for periostin production by both stromal and melanoma cellsGaëlle Tilman, Marina Mattiussi, Francis Brasseur, et al.
Pageof 5

Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
The New England Journal of Medicine|January 17, 2003
Immunosurveillance against cancer and immunotherapy--synergy or antagonism?Thierry Boon, Nicolas van Baren
Annals of the New York Academy of Sciences|May 9, 2013
Ongoing adaptive immune responses in the microenvironment of melanoma metastasesNicolas van Baren, Pierre G Coulie
Cancer Immunology Research|August 14, 2015
Tumoral Immune Resistance Mediated by Enzymes That Degrade TryptophanNicolas van Baren, Benoît J Van den Eynde
Seminars in Oncology|October 31, 2002
Peptide-based cancer vaccinesJean-Pascal Machiels, Nicolas van Baren, Marie Marchand
Frontiers in Immunology|February 19, 2015
Tryptophan-degrading enzymes in tumoral immune resistanceNicolas van Baren, Benoît J Van den Eynde
Journal of the European Academy of Dermatology and Venereology : JEADV|January 25, 2007
Is serum galectin-3 a potential predictor of the response to active specific immunotherapy in melanoma patients?Pierre Vereecken, Michel Heenen, Sajida Babar, et al.
Oncoimmunology|March 14, 2013
Lymphoid neogenesis in melanoma: What does it tell us?Nicolas van Baren, Jean-François Baurain, Pierre G Coulie
Cancer Immunology, Immunotherapy : CII|May 10, 2011
Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?Arcadi Cipponi, Grégoire Wieers, Nicolas van Baren, et al.
Oncoimmunology|July 9, 2015
Expression profile of the human IDO1 protein, a cancer drug target involved in tumoral immune resistanceNathalie Vigneron, Nicolas van Baren, Benoît J Van den Eynde
Molecular Cancer|December 19, 2007
Human periostin gene expression in normal tissues, tumors and melanoma: evidences for periostin production by both stromal and melanoma cellsGaëlle Tilman, Marina Mattiussi, Francis Brasseur, et al.
Pageof 5